Crosstalk between 5-HT2A and mGlu2 receptors: Implications in schizophrenia and its treatment

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

2 Scopus citations

Abstract

Schizophrenia is a psychiatric disorder that affects 1% of the population worldwide. The serotonin and glutamate receptor systems have been implicated in schizophrenia and its treatment. Serotonin 5-HT2A receptor is target of hallucinogens such as lysergic acid diethylamide (LSD) and psilocin, as well as involved in the mechanism of action of atypical antipsychotic drugs such as clozapine and risperidone. The metabotropic glutamate 2 (mGlu2) receptor modulates the physiological responses induced by the 5-HT2A receptor, and preclinical and clinical work suggests that this glutamate receptor may represent a new approach to treat schizophrenia. Here we review recent advances in our understanding of the crosstalk between these two receptors, as well as their implication in schizophrenia and antipsychotic drug action.

Original languageEnglish
Title of host publicationReceptors
PublisherHumana Press Inc.
Pages147-189
Number of pages43
DOIs
StatePublished - 2018
Externally publishedYes

Publication series

NameReceptors
Volume32
ISSN (Print)1048-6909
ISSN (Electronic)2524-6488

Keywords

  • 5-HT receptor
  • Antipsychotic
  • Clozapine
  • G protein-coupled receptor (GPCR)
  • GPCR dimer
  • GPCR heterocomplex
  • Glutamate
  • Lysergic acid diethylamide (LSD)
  • Metabotropic glutamate 2 receptor
  • Psychosis
  • Schizophrenia
  • Serotonin
  • mGlu2

Fingerprint

Dive into the research topics of 'Crosstalk between 5-HT2A and mGlu2 receptors: Implications in schizophrenia and its treatment'. Together they form a unique fingerprint.

Cite this